Key Takeaways
- Gilead Sciences has agreed to purchase German biotechnology firm Tubulis GmbH in a transaction valued at up to $5 billion, including $3.15 billion upfront.
- The acquisition bolsters Gilead’s antibody-drug conjugate (ADC) portfolio, with programs aimed at ovarian cancer and non-small cell lung cancer.
- RBC Capital Markets increased its GILD price target from $118 to $123 while maintaining a Sector Perform rating.
- RBC projects Yeztugo could exceed Q1 expectations by approximately $180 million, though concerns remain around compliance rates and market penetration.
- Multiple analysts including Cantor Fitzgerald, UBS, and Deutsche Bank maintain bullish stances with Buy or Overweight ratings and price targets reaching $155.
Gilead Sciences (GILD) is strengthening its oncology pipeline through a strategic acquisition of Tubulis GmbH, a Munich-based biotechnology company, in a cash deal worth up to $5 billion.
Gilead Sciences agrees to buy private German biotech Tubulis in a deal worth up to $5 billion as it looks to boost its portfolio in a hot new area of cancer drug development, sources say https://t.co/KRZYp5EQv0
— Bloomberg (@business) April 7, 2026
The pharmaceutical giant will pay $3.15 billion at closing, with an additional $1.85 billion potentially payable upon achieving specific development and commercial milestones. Gilead intends to finance the transaction through existing cash reserves and the issuance of senior unsecured notes, anticipating completion during the second quarter of 2026.
Tubulis specializes in developing antibody-drug conjugates, an innovative cancer treatment modality that delivers chemotherapy agents directly to malignant cells while minimizing damage to surrounding healthy tissue. The company’s primary asset, TUB-040, is currently undergoing Phase 1b/2 clinical evaluation for platinum-resistant ovarian cancer and non-small cell lung cancer.
Chief Executive Officer Daniel O’Day characterized the enhanced pipeline as potentially among the most robust and diversified in the company’s entire history.
Shares retreated approximately 1.37% following Tuesday’s announcement, a common market response when companies commit substantial upfront capital to acquisitions.
RBC Capital Increases Target While Maintaining Neutral Rating
RBC Capital Markets adjusted its GILD price objective upward to $123 from $118 while retaining its Sector Perform rating, which signals a neutral position. The investment firm highlighted encouraging early performance data for Yeztugo, one of Gilead’s recently launched products, based on third-party prescription tracking.
RBC’s analysis suggests Yeztugo may surpass Q1 consensus estimates by approximately $180 million, compared to the Street’s expectation of $141 million. Should this projection materialize, it would represent a significant outperformance.
However, RBC expressed some reservations. The firm observed that buy-side analysts have already incorporated ambitious full-year 2026 projections of approximately $1 billion. If patient compliance metrics or market penetration fail to meet expectations, these optimistic peak revenue forecasts may require downward revision.
Current compliance rates are tracking near 70% according to RBC’s market checks — a respectable figure, though one that provides limited cushion for deterioration.
RBC also identified potential weakness in other segments. The firm’s HIV revenue estimate stands at $4.8 billion compared to the Street consensus of $4.9 billion, while Veklury revenue is projected at $141 million versus the consensus estimate of $216 million.
Gilead is scheduled to release its first-quarter financial results on April 23.
Analyst Community Remains Generally Optimistic
Several analysts maintain positive outlooks on the stock. Cantor Fitzgerald reaffirmed its Overweight rating with a $155 price objective, highlighting robust prescription volume trends throughout Gilead’s HIV product portfolio.
UBS also sustained its Buy rating, referencing a 56% sequential increase in Yeztugo sales during February. Deutsche Bank similarly maintained its Buy rating and $155 target, forecasting first-quarter Yeztugo revenue of approximately $118 million.
In a separate corporate action, Gilead has extended the expiration date for its tender offer to acquire Arcellx common stock to April 24, 2026. The offer provides $115.00 per share in cash, supplemented by contingent value rights linked to future commercial milestone achievements.
As the April 23 earnings date approaches, market participants will be closely monitoring whether Yeztugo’s promising early prescription data converts into actual revenue outperformance.
